Inactive

PRE-SOLICITATION NOTICE **NOTICE OF INTENT NOI-NIAID-23-2170831 NAICS – 334516 This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID)... PRE-SOLICITATION NOTICE **NOTICE OF INTENT NOI-NIAID-23-2170831 NAICS – 334516 This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Agilent Technologies Inc to SurePrint G3 Custom Comparative Genomic Hybridization (CGH) Microarray slides as they pertain to research within the NIH Clinical Center. The National Institute of Allergy and Infectious Disease (NIAID) Division of Intramural Research (DIR) scientists study all aspects of infectious diseases, including the causative agent, vectors, and pathogenesis in human and animal hosts. Clinical research is an integral part of this mission, enabling key lab discoveries to be rapidly translated into methods to prevent, diagnose, or treat disease. DIR researchers annually conduct more than 200 clinical trials at the NIH Clinical Center on the Bethesda, Maryland, campus and at collaborating U.S. and international sites. In support of clinical research, the NIAID Centralized Sequencing Program is comprehensive program that obtains genetic testing, harmonizes phenotypic and genomic data, performs variant interpretation, and provides clinically validated results for patients enrolled in a diverse set of protocols at the NIH Clinical Center. The goal of the NIAID Centralized Sequencing Program is both to contribute to the understanding of underlying genetic etiology of disease and to address the clinical need for genomic evaluations. Ordering these CMA slides is an integral part of being able to perform the overall genetic testing evaluations. Required are: SurePrint G3 Custom CGH Array 4x180K 60-mer, 180K features, one 1 in x 3 in slide, four microarrays per slide to performNIAID Custom Clinical Chromosomal Microarray Analysis (N = 41) These custom slides will allow for the processing and analysis of comparative genomic hybridization microarrays purchased by NIAID in support of copy number variation analysis of patients admitted to the NIH Clinical Center under NIAID clinical protocols. These slides will allow copy number variation analysis of over 2000 target genes selected by NIAID that cause, or are suspected to cause, immunological diseases in this patient population. The Contractor shall supply microarray chips for the NIAID custom clinical chromosomal microarray analysis. NIAID will supply patient samples. NIAID will also supply provide plates for shipping and all consumable reagents. Turn-around time for microarray chip is 4 weeks from the time the contractor receives the order request. Microarray chips must be compatible with copy number variation analysis as performed by additional outside vendor. The statutory authority for this sole source requirement is 41 U.S.C. 1901(e)(2) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-23-2170831) to Dana Monroe at dana.monroe@nih.gov by 5:00 pm eastern time Monday, June 19, 2023. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.